Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study
2024

Improving Quality of Life for Multiple Sclerosis Patients with Alemtuzumab

Sample size: 165 publication 10 minutes Evidence: moderate

Author Information

Author(s): Meca-Lallana José Eustasio, Eichau Sara, Casanova Bonaventura, Rodríguez Elena Álvarez, Pato Antonio, Forner Mireia, Toledo Baldo

Primary Institution: Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

Hypothesis

The study aimed to evaluate the quality of life of patients treated with alemtuzumab in clinical practice.

Conclusion

Patients experienced significant and sustained improvements in their quality of life and functioning over three years of treatment with alemtuzumab.

Supporting Evidence

  • MSIS-29 physical domain scores decreased significantly over three years.
  • MSIS-29 psychological domain scores also showed significant reductions.
  • Annualized relapse rate decreased by 83% during the treatment period.
  • 81.5% of patients were free from radiological activity at three years.
  • 87% of patients were free from disability worsening after three years.

Takeaway

This study shows that alemtuzumab helps people with multiple sclerosis feel better and live better lives over three years.

Methodology

A prospective 3-year multicenter study was conducted with adult patients diagnosed with relapsing-remitting multiple sclerosis who started alemtuzumab treatment.

Potential Biases

Potential biases may arise from the observational nature of the study and the lack of a control group.

Limitations

The study lacked a comparator group and included patients with mild symptoms, which may limit the generalizability of the findings.

Participant Demographics

Mean age of participants was 38.6 years, with 67.9% being female.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI: 0.10–0.23

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s41687-024-00822-9

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication